Background-Peripartum (PP) cardiomyopathy (CM) is a rare condition of unknown etiology that occurs in late pregnancy or early postpartum. Initial evidence suggests that genetic factors may influence PPCM. This study evaluated and replicated genome-wide association of single nucleotide polymorphisms with PPCM.
PPCM pathophysiology may be distinct from idiopathic dilated cardiomyopathy, but this is uncertain. PPCM may arise from an immunologic response to autoantibodies 8 -10 or virus-associated inflammation, based on the finding of viral genomes in endomyocardial biopsy. 11 It may also occur as a maladaptive response to the stress of pregnancy, perhaps from catecholamine myocyte toxicity. 1 PPCM may require long-term pharmacological therapy, but this is unclear, as are its maternal and fetal risks in subsequent pregnancies.
Genetic factors may play a role in PPCM. Various other cardiomyopathies have a genetic basis, 12 and PPCM has disparate incidences across ethnic groups. [2] [3] [4] [5] Familial influences on PPCM are reported, [13] [14] [15] but evidence of a genetic component has not been proven. The genome-wide association study (GWAS) is a case-control approach for discovering single nucleotide polymorphisms (SNPs) associated with a phenotype (eg, References 16 through 20) . 16 -20 The present study sought to identify genetic loci associated with PPCM, using a 2-stage GWAS design.
Methods

Study Populations
The Utah Affiliated Hospitals Heart Failure Clinical Research Network PPCM registry was created in 2006. Ascertainment of PPCM cases utilized 4 mechanisms: (1) patients within Intermountain Healthcare were identified by ICD-9 codes, (2) patients treated in the Heart Failure Prevention and Treatment Program at Intermountain Medical Center were identified by records review, (3) health care providers across numerous specialties were invited to refer PPCM patients, and (4) a media campaign across Utah was conducted. The Intermountain Healthcare and University of Utah Institutional Review Boards approved this project and all participants provided written informed consent. A description of the study design is provided in Figure 1 . Genotyping methods and variable definitions are provided in the online-only Data Supplement text.
Genome-Wide Association Study
A total of 77 patients Ն18 years of age were identified from 2006 to 2008 as potential PPCM cases. PPCM phenotype was assigned based on clinical parameters gathered locally or through medical records (ie, history and physical examination, echocardiogram or-in its absence-another measure of left ventricular function, discharge summary, and other outpatient records). Patients meeting the strict definition of PPCM, based on the National Institutes of Health (NIH) criteria had symptomatic left systolic dysfunction (left ventricular ejection fraction [LVEF]Յ45%), diagnosis within the last month of pregnancy through the fifth postpartum month, unknown heart failure etiology, and no diagnosis of heart disease before the final month of pregnancy. 1 Categorization of cases was performed independently by a cardiologist with heart failure expertise and 2 nurse practitioners, and these assignments were verified or reassigned by another heart failure cardiologist. Of the 77 potential PPCM cases, 41 were found to meet definite criteria for PPCM. Five cases were of non-European ancestry, but no correction was made for population stratification (ie, confounding by ethnicity) in favor of determining the ability to replicate in an independent population.
Two independent sets of control groups were ascertained for GWAS. The first and primary control set was European-ancestry postmenopausal women (nϭ49) with parity Ն1 who were free from cardiovascular diseases. These patients, designated "local control subjects," were identified from the cardiac catheterization laboratory registry of the Intermountain Heart Collaborative Study. Exclusion of cardiovascular diseases was based on a lack of clinically diagnosed heart failure, angiographic evidence of no coronary disease (no coronary stenosis was Ն10%), and a lack of cardiac valve diseases, cardiac arrhythmias, and cerebrovascular and peripheral vascular conditions. DNA samples from the 41 PPCM case women and the 49 local control subjects were genotyped using the Illumina HumanHap 550K BeadChip SNP microarray, a sample size similar to another recent GWAS we reported. 21 Genotyping was performed by deCODE Genomic Services (Reykjavik, Iceland). One internal CEPH control was used on each DNA plate, and comparison of all control subjects was made across this and other GWAS projects run by the laboratory to track genotype calling. SNP calling and genotype clustering used automated Illumina software.
Call rates (genotypes/total number of SNPs) were computed for each DNA sample. Quality control evaluated the per-SNP and per-participant quality, with a minimum threshold of 95% genotyping success designated for inclusion in analyses of cases and local control subjects. SNPs were also excluded if they were subpolymorphic (minor allele frequency [MAF]Ͻ0.01). For SNPs, 99.8% of those with PϽ0.05 passed genotyping quality control. All PPCM cases and local control subjects passed genotyping quality control (89 had 99.0% to 99.3% success; 1 had 96.9%). Hardy-Weinberg equilibrium was considered violated at PϽ0.0001.
The second GWAS control set was drawn from anonymous participants in Illumina's iControlDB. Genotyping of iControls was Figure 1 . A 2-stage genome-wide association study design with multiple additional control verifications for independent discovery and replication peripartum cardiomyopathy (PPCM) case populations, and an exploratory evaluation for pregnancyassociated cardiomyopathy (PAMC) cases. SNP indicates single nucleotide polymorphism.
performed previously using the Illumina HumanHap 550K Bead-Chip. For more information on iControls and iControlDB, navigate to http://www.illumina.com/science/icontroldb.IM. Others have used iControls to study cancer. 22 The ethnicity, age, and sex of iControls were known, but phenotypes were not known. From the thousands of possible iControls to study, those included in the present study (nϭ654) were women of European ancestry who were Ն30 years of age and had 550K GWAS data available.
Replication Study
For replication, a new set of European-ancestry PPCM cases (designated "PPCM2" to distinguish from GWAS cases) and 3 control groups were ascertained. PPCM2 cases (nϭ30) were recruited during 2008 to 2010, using the same methods as GWAS cases. Another set of age-discordant European-ancestry female control subjects (designated "local2," nϭ124) were recruited based on the same methods and cardiac registry source as the GWAS local control subjects, with the additional caveat that local2 were free from hypertension, diabetes, and renal failure. The comparison of PPCM2 to local2 was designated as the primary hypothesis test to match the primary GWAS comparison.
The second replication control set was younger-age female Europeanancestry control subjects (YC, nϭ89) of reproductive age and unknown parity who underwent coronary angiography and were phenotypically similar to local and local2 control subjects, except in age. The third replication control set included European-ancestry obstetric patients who were free from both preeclampsia and PPCM and who delivered at the University of Utah Hospital (obstetric control subjects [OBC], nϭ90).
Pregnancy-associated cardiomyopathy (PACM) was defined as women diagnosed with cardiomyopathy who did not meet all of the National Institutes of Health PPCM criteria. 5 Ten PACM cases were enrolled during the GWAS phase and 19 during the replication phase, resulting in a PACM sample of nϭ29 cases.
As an exploratory analysis, obstetric patients from the University of Utah who had preeclampsia but were free from PPCM/PACM were ascertained to test whether rs258415 predicts preeclampsia.
Statistical Analysis
GWAS associations of SNPs with PPCM were performed under the additive genetic model using the allelic 2 test (Fisher exact test) in DiseaseMinerLite (deCODE Genetics, Reykjavik, Iceland). Odds ratios (ORs) and 95% confidence intervals (CI) for PPCM were calculated by comparing carriage of the minor allele to the major allele. The probability threshold for statistical significance was set at PϽ9.0ϫ10 Ϫ8 to correct for the increased type I error, due to the number of potentially independent SNP tests. Suggestive GWAS significance was taken to be PՅ1ϫ10 Ϫ5 . Correction for underlying population stratification was performed using efficient mixed-model association (EMMA-X), 23 and the genomic inflation factor (GIF) was calculated in PLINK and compared with results from EMMA-X.
Analyses in the replication study were performed under the additive genetic model, using the Armitage test of trend (which is asymptotically equivalent to the allelic 2 test). Because of the small case sample size that was available and the success in detecting one SNP at genome-wide significance, the primary replication hypothesis test was designated as the association of rs258415 with PPCM2 cases versus local2 control subjects. Statistical significance was set at PՅ0.05 for replication. This test was estimated to have 80% power to detect an OR of 3.5 per allele (␣ϭ0.05, 2-sided testing) when evaluating 30 PPCM2 cases and 4 local2 control subjects per case, assuming rs258415 MAF in control subjects was the same as in GWAS for local control subjects (MAFϭ0.27).
Comparisons of PPCM2 cases to YC or OBC were used to verify the MAF of the local2 control subjects. Analyses of PACM cases compared with the control sets were considered hypothesisgenerating. Age adjustment was performed when comparing PPCM2 with YC to evaluate if the age-discordant design (used to maximize phenotypic differences between cases and control subjects in primary GWAS and replication analyses) produced aberrant results as the result of age-dependent differences (eg, exceptional longevity of control subjects). Analysis of rs258415 was also performed for PPCM2 versus PACM cases.
To determine whether rs258415 simply predicts preeclampsia, MAFs were examined between GWAS cases with and without preeclampsia and in PPCM2 cases. The non-PPCM preeclampsia patients were also evaluated for rs258415 compared with OBC to evaluate prediction of preeclampsia.
Finally, HapMap linkage disequilibrium (LD) data for 252 SNPs including rs258415 was queried from http://hapmap.ncbi.nlm.nih.gov/ for a 200 kb region on chromosome 12p11.22 from approximately 10 kilobases beyond KLHDC5 to 10 kilobases beyond PTHLH.
Results
Genome-Wide Association Study
In the 41 PPCM patients, average age at diagnosis was 50 years less than the local control diagnosis age and 18 years less than the iControl enrollment age ( Table 1 ). LVEF range was also discordant: 10% to 44% in PPCM cases and 56% to 89% in local control subjects. Among PPCM cases, only 1 had a first-degree relative with cardiomyopathy, and 10% underwent cardiac transplantation. Other characteristics are shown in Table 1 . A plot of observed and expected probability values (online-only Data Supplement Figure SI ) demonstrated that more than the expected number of SNPs were found to have PՅ1ϫ10 Ϫ5 .
PPCM Cases Versus Local Control Subjects
One SNP on chromosome 12 (rs258415) achieved genomewide significance for PPCM cases compared with local control subjects (MAFs: 0.68 versus 0.27; Pϭ2.06ϫ10 Ϫ8 ; OR, 5.96 per C allele; 95% CI, 3.13 to 11.38). Post hoc analysis excluded the 5 minority PPCM cases (12% of cases) and showed a similar result (Pϭ7.91ϫ10 Ϫ8 ; OR, 5.90 per C allele; 95% CI, 3.02 to 11.51).
On the basis of the potential function of PTHLH in preeclampsia, 24 rs258415 MAFs were compared between cases with and without preeclampsia. The frequency of the C allele was not different (0.72 versus 0.68, Pϭ0.78), based on preeclampsia status.
Suggestive significance compared with local control subjects was found for 13 other SNPs representing 7 distinct loci ( Table 2) . Although a prior animal model for PPCM implicated the STAT3 gene, 25 no SNP in the STAT3 gene had PϽ0.05. The closest SNP on chromosome 17 with PϽ0.05 for discovery PPCM cases versus local control subjects was near the LGP2 gene, about 200 kilobases from STAT3 (rs2079009: Pϭ0.016).
Rs258415 retained genome-wide significance (Pϭ1.62ϫ10 Ϫ11 ) when corrected for population stratification using EMMA-X, but only 6 other SNPs (rs7102702, rs10048187, rs4458717, rs12881957, rs7152674, and rs3784064) had PՅ1ϫ10 Ϫ5 . EMMA-X analysis produced GIFϭ0.993 compared with the uncorrected GIF of 1.106. 
PPCM Versus iControls
PPCM SNP Replication Study
Characteristics of replication cases and control subjects are provided in Table 1 . LVEF range was 10% to 45% in PPCM2 cases versus 45% to 89% in local2 control subjects and 45% to 83% in YC. No transplants have been performed as yet in these cases, but 10% required mechanical circulatory support as a bridge to transplant. 
PPCM2 Cases Versus Local2 Control Subjects
PPCM2 Versus YC and Versus OBC
The replication findings above were further verified (see Figure 2 ) by comparison of PPCM2 to YC (MAF: 0.32 versus 0.182; Pϭ0.029) and to OBC (MAF: 0.32 versus 0.178; Pϭ0.013). Adjustment for age in comparisons of PPCM2 with YC changed the regression ␤-coefficient of the SNP only 2.5%, indicating that age did not confound the association. PPCM2 compared with all 3 control sets combined produced Pϭ0.006.
PPCM2 Versus iControls
Post hoc comparison of PPCM2 cases to iControls also showed nominal significance (Pϭ0.041; OR, 1.79 per C allele; 95% CI, 1.02 to 3.14).
PACM Cases and Replication Control Subjects
No difference in rs258415 genotype distribution was found between PPCM2 and PACM cases (0.32 versus 0.27, Pϭ0.65). For PACM cases versus local2 control subjects (Pϭ0.06), YC (Pϭ0. 14) , and OBC (Pϭ0.038), rs258415 had an effect similar to its effect in PPCM2 cases (Figure 2 ), although the statistical significance was borderline. PACM compared with the combined 3 control groups produced Pϭ0.035. Figure 3 shows the LD between rs258415 and 251 SNPs (based on r 2 ) across chromosome 12p11.22 in HapMap data and online-only Data Supplement Figure SII shows the DЈ pattern in the same region.
Table 1. Baseline Characteristics (Mean؎SD or Proportions) for Each of the Case and Control Groups Included in the Genome-Wide Association Study and Replication Studies
LD Structure
Discussion
The primary objective of this study was to discover genetic markers across the genome that are associated with PPCM.
Using an agnostic approach for locus candidacy and a genome-wide SNP array for genotyping, 41 women with a clean, narrowly defined PPCM phenotype were compared with 49 elderly women who were free from heart diseases. An independent replication population of similar sample size validated GWAS findings for a SNP that achieved genomewide significant association with PPCM: rs258415 on chromosome 12p11.22. That SNP had a similar effect on PACM, a less stringently delineated phenotype that some assert is the same as PPCM, 5 although statistical significance for PACM (excluding PPCM cases) was borderline. This study indicates SNP indicates single nucleotide polymorphism; PPCM, peripartum cardiomyopathy; OR, odds ratio; and CI, confidence interval. One SNP (rs258415) achieved genome-wide significance versus local control subjects despite the unorthodox sample size (P values for discovery PPCM cases versus iControls are also indicated).
For discovery PPCM cases versus iControls: *Pϭ7.92ϫ10 Ϫ19 , †PϽ9.0ϫ10 Ϫ8 , and ‡PϽ0.001.
Figure 2.
Replication study. Forest plot for rs258415 associations with peripartum cardiomyopathy (PPCM2) cases compared with local2 control subjects, young control subjects, obstetric control subjects, and the combination of all 3 control groups. Results for the same comparisons using pregnancy-associated cardiomyopathy (PACM) cases are also provided. All odds ratios are per C allele and the x-axis is on the log 10 scale.
that genetic factors contribute to PPCM and provides a significant, validated locus near the PTHLH and KLHDC5 genes.
As anticipated in the study design of this small-sample-size GWAS, a SNP with replicable association with PPCM was enriched for its minor allele in the GWAS discovery cases (MAFϭ0.68 for rs258415) compared with the replication PPCM2 and PACM cases (MAFϭ0.32 and 0.27, respectively). The MAF of that SNP was very similar and stable across all control subjects, with MAFϭ0.27 in the GWAS local control subjects and MAFϭ0.16 to 0.21 for iControls, local2 control subjects, YC, and OBC. Because of the strength of association of that locus and the extreme-phenotype GWAS/replication design, statistical significance could be detected and replicated despite the unorthodox sample size.
PPCM occurs among "healthy" women during a period of life that would otherwise be "normal" and can be shocking and devastating to individuals and their families. Genetic evidences in the context of enhanced knowledge regarding the natural history of PPCM may assist in alleviating concerns for the at-risk population. This may include development of better screening strategies, enhanced understanding of the necessary duration of medical management, possible preventative strategies, and improved knowledge regarding the likelihood of recurrent PPCM with a subsequent pregnancy. Because of the potential for clinical genetic testing among women who are pregnant, this study compared rs258415 between PPCM cases and a secondary control group of otherwise healthy obstetric patients. Prospective studies are required to evaluate the clinical utility of genetic screening for PPCM.
PPCM is considered a rare condition but may be misrepresented by the narrow time window that strict definitions impose. One population-based estimate of PPCM incidence suggests a rate of 1 in 3189 live births. 2 PPCM is often missed as a diagnosis because, although greater in severity, symptoms mimic usual concerns during pregnancy and often occur before the last antepartum month. PACM is a more inclusive definition of the condition but may encompass a more heterogeneous phenotype. Various risk factors and mechanisms for PPCM/PACM have been proposed, [1] [2] [3] 5 yet answers are scarce. Diagnosis carries a similar burden as other forms of heart failure where structural heart pathology may not return to normal and symptoms persist.
A variety of genes for idiopathic cardiomyopathy have been identified. 12, 26 Those loci include genes for the angiotensin I-converting enzyme and ␤-adrenergic receptors. 26, 27 The ␤-adrenergic receptor genes and others (eg, CYP2D6) are also implicated in pharmacogenetic interactions. 26 -28 A genetic basis for PPCM is controversial, with some mostly anecdotal reports noting familiality, [13] [14] [15] but other large case series not reporting family history as a PPCM risk factor. 5 Indeed, the European Society of Cardiology currently classifies PPCM as a nonfamilial, nongenetic form of dilated cardiomyopathy. 29 A genetic basis for PPCM has not been systematically studied.
Previously, gene-hunting studies were laborious and expensive. 30 GWAS using large SNP panels permits evaluation of unrelated individuals using traditional statistics and can be a more powerful means to assess genetic risk associations and isolate them to a small genomic region. Although a flood of recent GWAS have been published, (eg, chromosome 9p21 in coronary heart disease 17 ), most use large sample sizes because of small SNP effect sizes in common, heterogeneous diseases. Identifications of genome-wide loci using fewer than 100 cases has been performed for phenotypes such as macular degeneration, 18 esophageal cancer, 19 and bladder cancer. 20 This study extends the list to PPCM, a rare pheno- type that was tightly defined herein and studied using a small sample of cases.
On the basis of the population frequency of PPCM, a rare genetic variant would be expected to affect the disease, but rs258415 is common (ie, MAFs of 0.16 to 0.21 in iControls and replication study control subjects). On the basis of r 2 , high LD with other SNPs is limited to a 30-kb region ( Figure  3) ; thus, rs258415 may tag risk arising from intergenic variation. It may reside at a noncoding RNA locus (similar to the coronary disease 9p21 locus 31 ) or a regulatory element related to nearby genes. However, LD measured by DЈ (online-only Data Supplement Figure SII ) may be useful if the MAF of the causal SNP is small; thus, if a rare causal variant in LD with rs258415 has an even larger effect on risk, it may be tagged by rs258415 at the distances of the KLHDC5 or PTHLH genes, but this requires further evaluation.
Little is known about KLHDC5, a gene near rs258415, except that it is overexpressed in Sézary syndrome, an aggressive CD 4 ϩ cutaneous T-cell lymphoma. 32 Because PPCM may be an autoimmune disease with specific environmental triggers related to pregnancy, 9 that involvement in immune function may connect KLHDC5 to PPCM, but this is tenuous and speculative, requiring further study.
PTHLH (or PTHrP), the closest gene in the other genomic direction, is a member of the parathyroid hormone family. It has multiple alternatively-spliced transcripts encoding 2 isoforms and may have alternate non-AUG translation start codons.
The product of PTHLH, parathyroid hormone-related hormone (PTHrP), is involved in calcium transfer in the placenta and uterus where it regulates blood flow. 33 It is expressed due to mechanical uterine stretch during pregnancy and appears to be a key factor in preventing contractions until term. 33, 34 It is also potentially involved in the etiology of preeclampsia, with diminished levels resulting in decreased trophoblast apoptosis and abnormal trophoblast invasion. 24 PTHrP also plays a cardiovascular role by modulating ventricular contraction and by exerting control of pacing at the sinus node. 24 It influences contraction by reducing systemic blood pressure and by causing an inotropic effect on cardiac myocytes through calcium channel activation. 24 PTHrP is produced in the myocardium and may be expressed as the result of mechanical stretch. It has higher levels in patients with heart failure, 35 and those levels correlate positively with left ventricular end-diastolic and end-systolic parameters and negatively with LVEF. 35 Given these various roles, we hypothesize that an increase in PTHrP during pregnancy to prevent uterine contraction may lead a compromised heart into PPCM/PACM.
If the causal variant at chromosome 12p11.22 is common, like the C allele at rs258415, it may interact with another locus or an environmental factor to alter PPCM risk. Conversely, if rs258415 tags a rare variant, that rare variant may modify PTHLH transcription, structure, or translation. These hypotheses require further investigation. Additional investigation is also required to examine the suggestively-significant loci discovered by GWAS.
Strengths and Limitations
Limitations include the small sample size. Despite statistical significance, findings may not be generalizable to other PPCM cases because of the small set of chromosomes available for analysis. As noted in the online-only Data Supplement Materials, the minor allele in GWAS cases should be overrepresented because of the extreme phenotype strategy for locus identification and is not expected to represent the allele frequencies in the general population. Although unlikely because of the high quality of the genotyping by deCODE, the small case sample size may have allowed uncontrollable GWAS laboratory testing, allele assignment, or genotype clustering/calling errors to drive the results. Validations of the SNP associations among other populations (such as the replication sample herein) are required to understand the true allele frequencies in cases and control subjects, including in other ethnic groups.
Study strengths include the tightly defined case phenotype that maximized the detection of genetic factors and minimized statistical noise from indeterminate diagnoses. The 2-stage GWAS design with independent case sets for discovery and replication was also a strength.
Conclusions
A genome-wide significant association with PPCM was found for a genetic locus on chromosome 12p11.22, and this was replicated in an independent set of cases and control subjects. Although these associations do not prove causality, they indicate that genetic factors play a role in PPCM and set the stage for further clinical and pathophysiological investigation of genetic loci in PPCM, including for the rs258415 SNP. Additionally, these data suggest that PACM may be genetically similar to PPCM, but this requires additional evaluation.
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